Very excited to announce we have completed enrollment in our Japanese clinical study of our #celltherapy for #discdegeneration. Meanwhile in the U.S., all currently enrolled trial subjects have completed their one-year study visits. bit.ly/3tW5rmr

DiscGenics caps enrollment in lumbar disc degeneration study dlvr.it/RyYRXT

Clinical Launches & Updates ~DiscGenics completes patient enrollment in Japanese #ClinicalStudy  ~HOYA Vision Care Canada shares results of spectacle lens follow-up study ~Bio-Techne commercial release of novel DNAscope™

We are pleased to announce our participation in #CGMesa21 this week. Our Chairman & CEO Flagg Flanagan will give an update on the company’s U.S. and Japanese clinical programs evaluating IDCT for #degenerativediscdisease TODAY at 3:15PM PT. Learn more meetingonthemesa.com

Scientists DiscGenics are developing an allogeneic #celltherapy for the treatment of lumbar disc degeneration comprised of discogenic cells, that are grown in a sphere configuration. #stemcell #academictwitter #phdlife #cellculture Read more: ow.ly/tZI050Gqe2L

Congratulations to our Chairman & CEO Flagg Flanagan who was recognized by Goldman Sachs for #entrepreneurship at 2021 Builders + Innovators Summit. #GSInnovator bit.ly/DiscGenicsGSIn…

Our CEO & Chairman Flagg Flanagan will present an update on our US and Japanese clinical programs evaluating IDCT for #degenerativediscdisease at the 40th Annual J.P. Morgan Healthcare Conference on Tues., Jan 11, 2022 at 9:00AM EST. #JPM22 #JPM2022 bit.ly/DGxJPM22

Positive interim clin data for allogeneic #celltherapy for #degenerativediscdisease presented at #SpineSummit2022. High dose IDCT well tolerated, resulted in statistically significant, clinically meaningful improvements in pain, function & quality of life bit.ly/3tcqRwf

#DiscGenics Senior Process Engineer is in Dublin this week presenting at the Global Bioprocessing, Bioanalytics & ATMP Manufacturing Congress (Global Engage) on container closure integrity testing for #celltherapy. global-engage.com/event/bioproce…

If you’re attending the Alliance for Regenerative Medicine (ARM) #CGMesa22, don’t miss CEO Flagg Flanagan’s on-demand update on #DiscGenics first-in-human clinical study of its allogeneic discogenic progenitor #celltherapy for #degenerativediscdisease. bit.ly/3SGluB2

Matthew F. Gornet, MD will present 2-year clinical data from #DiscGenics study of injectable discogenic progenitor #celltherapy for #degenerativediscdisease at the NASS annual meeting in Chicago tomorrow! bit.ly/3rMMrXX #NASS22 #NASS2022

Our CEO & Chairman Flagg Flanagan will present an update on our recently completed US clinical study evaluating IDCT for #degenerativediscdisease at the 41st Annual J.P. Morgan Healthcare Conference on Wed., Jan 11, 2023 at 3:30PM. #JPM23 #JPM2023 prn.to/3i9REIc

Clinical Trial Results: Discogenic progenitor #celltherapy (IDCT) safely increased disc volume & provided rapid, durable improvements in low back pain, function, quality of life & pain med use out to 2 years in patients with #degenerativediscdisease. prn.to/3R1jhjM

FDA grants Regenerative Medicine Advanced Therapy (#RMAT) designation to IDCT because of its potential to address the unmet medical needs of millions of patients with painful #degenerativediscdisease! bit.ly/IDCT_RMAT

Thrilled to share highlights from our recent podcast with Merge Medical! Dive into the innovative world of DiscGenics and discover the transformative potential of IDCT. A must-listen for those passionate about the future of spinal health! #IDCT #RegenerativeMedicine #SpinalHealth

We're thrilled to announce that our CEO, FlaggFlanagan, will be presenting at the East-West BioPharma Summit from Oct 2-4 and the 2023 Cell & Gene Meeting on the Mesa from Oct 10-12. Learn more about the event in our press release! prnewswire.com/news-releases/…

We are proud to announce that we have partnered with the U.S. Department of Veterans Affairs (VA) to explore the synergy of our Discogenic Cells with the VA's advanced disc-like angle ply structure. Pushing boundaries in spinal health! prnewswire.com/news-releases/…

DiscGenics Chairman & CEO FlaggFlanagan to present at #CanaccordGenuity 2024 Musculoskeletal Conference prn.to/4bxu7ro #aaos2024

We are excited to announce that the U.S. FDA has allowed Phase III clinical evaluation of our allogeneic, injectable disc progenitor #celltherapy (IDCT) for painful lumbar #degenerativediscdisease to proceed. Subject enrollment expected to begin Q4 2024. bit.ly/3xX8cv4

Congrats to DiscGenics for announcing the FDA has allowed Phase III clinical evaluation of their allogeneic, injectable disc progenitor cell therapy for painful lumbar #degenerativediscdisease to proceed. Link below for details. #UtahLifeSciences ow.ly/2xlM50SCGE7